Angina Pectoris: Clinical Trials

107 trials for Angina Pectoris, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 completed, 24 unknown, 8 terminated, 3 recruiting. 107 Phase 3, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3107Completed 65, Unknown 24, Terminated 8, Recruiting 3, Active not recruiting 2, Enrolling by invitation 2, Not yet recruiting 1, Suspended 1, Withdrawn 1
Phase 215Completed 7, Unknown 5, Enrolling by invitation 1, Recruiting 1, Terminated 1

Follow Angina Pectoris: new trials by email Literature Review of Angina Pectoris trials Research Report on Angina Pectoris

Trials (filtered) newest first · largest first

All 107 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nebivolol ANOCA Treatment Randomized Trial
Nevibolol, Placebo - ANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD)
Phase 3Not yet recruitingSpanish Society of Cardiology1502025-04-012025-01-01
Personalized Evaluation of Susptected Myocardial Ischemia
Clinical Likelihood (CL) Model-Based Diagnostic Strategy, Standard of care treatment - Chronic Coronary Syndrome, Angina Pectoris
Phase 3Enrolling by invitationGødstrup Hospital20002024-11-202025-12-19
Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm
Endothelin Receptor Antagonist, Placebo control - Coronary Spasm
Phase 2 / Phase 3Enrolling by invitationRadboud University Medical Center1002024-11-112024-11-18
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
Amlodipine, Nebivolol, Placebo - Angina Pectoris, Microvascular Angina
Phase 2 / Phase 3RecruitingStanford University1502024-10-102024-11-27
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
Colchicine 0.5 MG, Ticagrelor 90mg, Aspirin 75-300mg - Stroke, Stroke, Ischemic
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris28002023-05-172025-09-08
Prasugrel Or Ticagrelor De-escalation in NSTE-ACS
De-escalation to ticagrelor 60 mg at day 30, De-escalation to prasugrel 5 mg at day 30, Switch to ticagrelor 60 mg at day 45 - Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
Phase 3UnknownCollegium Medicum w Bydgoszczy502023-04-012023-03-22
Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
Ad5FGF-4, Placebo - Angina, Stable
Phase 3UnknownAngionetics Inc.1602023-01-012022-07-19
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Prednisolone, Losartan - COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle
Phase 3Active not recruitingValentina Puentmann2792022-12-122025-12-09
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome
Ticagrelor 90mg, Ticagrelor 60mg, Aspirin - STEMI, NSTEMI
Phase 3UnknownCollegium Medicum w Bydgoszczy45002022-02-072023-04-21
Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography
Dapagliflozin 10Mg Tab, Placebo - Diabete Type 2, Unstable Angina
Phase 3CompletedHilda Elizabeth Macías Cervantes542021-06-212023-08-21
Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms
Allopurinol 300 MG, Placebo oral tablet - Refractory Angina
Phase 2 / Phase 3UnknownMinistry of Health, Brazil402021-03-032021-02-24
Rhodiola Rosea for Coronary Microvascular Disease
Rhodiola Rosea Capsules, Placebo - Coronary Microvascular Disease
Phase 2 / Phase 3UnknownQilu Hospital of Shandong University1142020-01-012020-01-06
Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial
Diltiazem Hydrochloride, Placebo - Microvascular Angina, Coronary Vasospasm
Phase 3Active not recruitingRadboud University Medical Center852019-10-252023-03-30
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina
T89 capsule, Placebo capsule - Chronic Stable Angina Pectoris
Phase 3RecruitingTasly Pharmaceuticals, Inc.7652019-08-012025-04-09
Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes
Double Dose Quadrivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine - Acute Coronary Syndrome
Phase 3CompletedHospital Israelita Albert Einstein18012019-07-192022-08-31
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
Vitamin E, N-acetyl cysteine, Placebo oral capsule - Coronary Artery Disease, Coronary Artery Angiography
Phase 3UnknownRajaie Cardiovascular Medical and Research Center10002018-11-012018-11-30
Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes
trimetazidine, Placebo Oral Tablet - Diabetes Mellitus, Angina, Unstable
Phase 3UnknownUniversity of Sao Paulo General Hospital1202018-10-012018-10-24
Effect of External Counter Pulsation on Coronary Artery Disease
External Counter Pulsation - Stable Chronic Angina, Coronary Artery Disease
Phase 3UnknownEighth Affiliated Hospital, Sun Yat-sen University3802018-06-082017-12-13
The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery
Ticagrelor, Placebo - Coronary Artery Disease, Stable Angina
Phase 3UnknownJ.M. ten Berg4872015-03-012020-04-27
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Eleclazine, Placebo - Hypertrophic Cardiomyopathy
Phase 2 / Phase 3TerminatedGilead Sciences1722015-02-052018-09-24

Showing 20 of 107. Sign in to see all of them.

Narrower conditions

Angina, Unstable (43)  ·  Myocardial Infarction (31)  ·  Coronary Artery Disease (29)  ·  Angina, Stable (28)  ·  Acute Coronary Syndrome (27)  ·  Myocardial Ischemia (25)  ·  Heart Diseases (13)  ·  Cardiovascular Diseases (11)  ·  Coronary Disease (11)  ·  Non-ST Elevated Myocardial Infarction (6)  ·  Microvascular Angina (5)  ·  Angina Pectoris, Variant (4)  ·  Atherosclerosis (4)  ·  Chest Pain (4)

Broader conditions

Vascular Diseases (106)  ·  Pathological Conditions, Signs and Symptoms (105)  ·  Neurologic Manifestations (104)  ·  Pain (104)  ·  Signs and Symptoms (104)  ·  Chest Pain (100)  ·  Cardiovascular Diseases (96)  ·  Heart Diseases (94)  ·  Myocardial Ischemia (82)  ·  Pathologic Processes (38)  ·  Infarction (35)  ·  Necrosis (35)  ·  Ischemia (33)  ·  Arterial Occlusive Diseases (30)

Interventions

Clopidogrel (8)  ·  Aspirin (6)  ·  Ticagrelor (6)  ·  Ranolazine (5)  ·  Adenosine (3)  ·  Enoxaparin (3)  ·  Influenza Vaccines (3)  ·  Abciximab (2)  ·  Angioplasty, Balloon, Coronary (2)  ·  Cilostazol (2)  ·  Coronary Artery Bypass (2)  ·  Oxygen (2)  ·  Percutaneous Coronary Intervention (2)  ·  Prasugrel Hydrochloride (2)  ·  Rivaroxaban (2)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (5)  ·  Cardium Therapeutics (4)  ·  Gilead Sciences (4)  ·  Sanofi (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Centocor, Inc. (2)  ·  Collegium Medicum w Bydgoszczy (2)  ·  Karolinska Institutet (2)  ·  Korea Otsuka Pharmaceutical Co., Ltd. (2)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2)  ·  Ministry of Health, Brazil (2)  ·  Organon and Co (2)  ·  Pfizer (2)  ·  Radboud University Medical Center (2)  ·  Shahid Beheshti University of Medical Sciences (2)

Countries

United States (27)  ·  Canada (14)  ·  Germany (13)  ·  Netherlands (13)  ·  Brazil (10)  ·  Italy (10)  ·  Russia (10)  ·  Poland (9)  ·  United Kingdom (9)  ·  France (8)  ·  Sweden (8)  ·  China (7)  ·  Australia (6)  ·  Belgium (6)  ·  Israel (6)

Top investigators

Ali Eskandari, MD (2)  ·  Hossein Vakili, M.D. (2)  ·  Maryam Keshtkar-Jahromi, M.D.; M.P.H. (2)  ·  Neville Suskin, MBChB, MSc (2)  ·  Paul Foster, MD (2)  ·  Robert L. Rolleri, Pharm.D. (2)  ·  Seyed Mostafa Razavi, MD (2)  ·  Sharareh Gholamin, MD (2)  ·  Adolph Hutter (1)  ·  Alfredo Zuppiroli, MD (1)  ·  Andras Komocsi, MD PhD (1)  ·  Andrew Wallace (1)  ·  Benjamin Terrier, MD, PhD (1)

Results publications

PMID 17825712, PMID 35224730, PMID 11239408, PMID 15238590, PMID 16304073, PMID 16537663, PMID 16875985, PMID 17010793, PMID 17124018, PMID 17299194, PMID 17368152, PMID 17456819, PMID 17637939, PMID 18056903, PMID 18196350, PMID 18331634, PMID 18376001, PMID 18440330, PMID 18502300, PMID 18765432, PMID 19022155, PMID 19033002, PMID 19061694, PMID 19136486, PMID 19171852, PMID 19270315, PMID 19298914, PMID 19332455, PMID 19349325, PMID 19371824, PMID 19389561, PMID 19460609, PMID 19463332, PMID 19463378, PMID 19608137, PMID 19628125, PMID 19699861, PMID 19717846, PMID 19825809, PMID 19843899, PMID 19853332, PMID 20026777, PMID 20031731, PMID 20060578, PMID 20079528, PMID 20118151, PMID 20124123, PMID 20142447, PMID 20194880, PMID 20298924

NIH funding

2018 (2), 1RC2HL101458-01 (1), 2005 (1), 2014 (1), R01HL031025 (1), R01HL042428 (1), R01HL050839 (1), R01HL076808 (1), U01HL038610 (1), U01HL064829 (1), U01HL077821 (1), U01HL077822 (1), U01HL077823 (1), U01HL077826 (1)